West Branch Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.66M | Buy |
30,433
+173
| +0.6% | +$37.2K | 1.78% | 15 |
|
|
2026
Q1 | $6.58M | Buy |
30,260
+167
| +0.6% | +$37K | 1.76% | 17 |
|
|
2025
Q4 | $6.88M | Buy |
30,093
+122
| +0.4% | +$27.8K | 1.77% | 17 |
|
|
2025
Q3 | $6.94M | Buy |
29,971
+321
| +1% | +$65.4K | 1.82% | 15 |
|
|
2025
Q2 | $5.5M | Buy |
29,650
+282
| +1% | +$52.4K | 1.63% | 18 |
|
|
2025
Q1 | $6.15M | Buy |
29,368
+625
| +2% | +$122K | 2.05% | 12 |
|
|
2024
Q4 | $5.11M | Sell |
28,743
-878
| -3% | -$161K | 1.63% | 16 |
|
|
2024
Q3 | $5.85M | Buy |
29,621
+252
| +0.9% | +$47K | 2.02% | 12 |
|
|
2024
Q2 | $5.04M | Sell |
29,369
-275
| -0.9% | -$45.6K | 1.87% | 11 |
|
|
2024
Q1 | $5.4M | Buy |
29,644
+400
| +1% | +$68.9K | 2.18% | 10 |
|
|
2023
Q4 | $4.53M | Buy |
29,244
+113
| +0.4% | +$16.5K | 2.13% | 11 |
|
|
2023
Q3 | $4.34M | Buy |
29,131
+164
| +0.6% | +$24.1K | 2.28% | 9 |
|
|
2023
Q2 | $3.9M | Buy |
28,967
+130
| +0.5% | +$19.1K | 1.95% | 12 |
|
|
2023
Q1 | $4.6M | Sell |
28,837
-2
| -0% | -$306 | 2.56% | 9 |
|
|
2022
Q4 | $4.66M | Sell |
28,839
-2
| -0% | -$307 | 2.88% | 9 |
|
|
2022
Q3 | $3.87M | Sell |
28,841
-32
| -0.1% | -$4.59K | 2.41% | 10 |
|
|
2022
Q2 | $4.42M | Sell |
28,873
-21
| -0.1% | -$3.21K | 2.56% | 9 |
|
|
2022
Q1 | $4.68M | Sell |
28,894
-236
| -0.8% | -$34.3K | 2.24% | 9 |
|
|
2021
Q4 | $3.94M | Sell |
29,130
-2
| -0% | -$236 | 1.68% | 15 |
|
|
2021
Q3 | $3.14M | Buy |
29,132
+2,275
| +8% | +$260K | 1.51% | 16 |
|
|
2021
Q2 | $3.02M | Buy |
26,857
+574
| +2% | +$64.6K | 1.49% | 17 |
|
|
2021
Q1 | $2.84M | Sell |
26,283
-911
| -3% | -$97.4K | 1.66% | 19 |
|
|
2020
Q4 | $2.91M | Sell |
27,194
-59
| -0.2% | -$5.67K | 1.72% | 16 |
|
|
2020
Q3 | $2.39M | Buy |
27,253
+259
| +1% | +$24.4K | 1.52% | 19 |
|
|
2020
Q2 | $2.65M | Buy |
26,994
+449
| +2% | +$39.5K | 1.87% | 14 |
|
|
2020
Q1 | $2.02M | Sell |
26,545
-1,061
| -4% | -$90.4K | 1.93% | 15 |
|
|
2019
Q4 | $2.44M | Sell |
27,606
-3,968
| -13% | -$329K | 1.7% | 16 |
|
|
2019
Q3 | $2.39M | Buy |
31,574
+6,903
| +28% | +$473K | 1.77% | 14 |
|
|
2019
Q2 | $1.79M | Sell |
24,671
-4,740
| -16% | -$373K | 1.48% | 17 |
|
|
2019
Q1 | $2.37M | Buy |
29,411
+2,031
| +7% | +$166K | 2.12% | 13 |
|
|
2018
Q4 | $2.52M | Sell |
27,380
-807
| -3% | -$71K | 2.66% | 9 |
|
|
2018
Q3 | $2.67M | Sell |
28,187
-1,463
| -5% | -$139K | 1.98% | 14 |
|
|
2018
Q2 | $2.75M | Buy |
29,650
+3,375
| +13% | +$330K | 2.17% | 13 |
|
|
2018
Q1 | $2.49M | Buy |
+26,275
| New | +$2.89M | 2.73% | 11 |
|
Other funds holding ABBV
LMFP
HCM
AAMU
HPC
CRM
CNB
West Branch Capital's ABBV Position: Q2 2026 in Review
West Branch Capital increased its AbbVie (ABBV) stake by 0.57% in Q2 2026, buying an estimated $37.2K and bringing the position to 30,433 shares worth $7.66M. The position accounts for 1.78% of the portfolio, ranked #15.
West Branch Capital first reported a position in ABBV in Q1 2018 and has held it in 34 quarters since. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- West Branch Capital held 30,433 shares of AbbVie worth $7.66M as of Q2 2026.
- West Branch Capital bought 173 AbbVie shares in Q2 2026, an estimated $37.2K.
- AbbVie made up 1.78% of West Branch Capital's portfolio in Q2 2026, its #15 holding.
- West Branch Capital first reported a position in AbbVie in Q1 2018 and has held it in 34 quarters since.
- 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on West Branch Capital's 13F filing for Q2 2026, filed 10 Jul 2026.